Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1622 1626 1647
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18584311 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | Non-Final OA | Genentech, Inc. |
| 18697706 | INHIBITORS OF ALPHA-5 BETA-1 INTEGRIN AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 18481045 | WATER SOLUBLE FLUORESCENT OR COLORED DYES COMPRISING CONJUGATING GROUPS | Non-Final OA | SONY GROUP CORPORATION |
| 18293003 | (3-PIRYDYL)-QUINAZOLINE | Non-Final OA | BASF SE |
| 18272673 | SYNTHESIS OF POLYFLUORINATED ARYL AND HETEROARYL CARBOXAMIDES | Non-Final OA | BASF SE |
| 17912485 | SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 | Final Rejection | The Board of Regents of The University of Texas System |
| 18564748 | COMPOUNDS FOR THE TREATMENT OF SARS | Non-Final OA | Purdue Research Foundation |
| 18254094 | METHOD OF PREPARING HETEROGENEOUS LINEAR CARBONATE ADOPTING CATALYTIC FILTERING | Final Rejection | LOTTE CHEMICAL CORPORATION |
| 18684225 | Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide | Non-Final OA | Pfizer Inc. |
| 17637565 | COMPOSITION FOR PREVENTING OR TREATING BACTERIAL INFECTIOUS DISEASE COMPRISING 4-GINGEROL DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18682681 | PIPERAZINE-BASED AGONISTS OF LFA-1 AND VLA-4 | Non-Final OA | Texas Heart Institute |
| 18797649 | COMPOSITIONS, KITS, AND METHODS TO INDUCE ACQUIRED CYTORESISTANCE USING STRESS PROTEIN INDUCERS | Non-Final OA | FRED HUTCHINSON CANCER RESEARCH CENTER |
| 18823147 | TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USE | Non-Final OA | SPERO THERAPEUTICS, INC. |
| 18015309 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | XIZANG HAISCO PHARMACEUTICAL CO., LTD |
| 18234826 | 2-S RIMANTADINE AND 2-R RIMANTADINE FOR TREATING CANCER | Final Rejection | Toragen, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy